Stock Events

Stock Events

VYNE Therapeutics 

$0.61
46
-$0-0.41% Friday 20:00

Statistics

Day High
0.61
Day Low
0.61
52W High
1.99
52W Low
0.28
Volume
100,927
Avg. Volume
307,521
Mkt Cap
20.33M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.3
-0.25
-0.19
-0.13
Expected EPS
-0.18
Actual EPS
N/A

Financials

-4,646.14%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
1.14MRevenue
-52.97MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VYNE. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap187.56B
Amgen is a biotech company that develops treatments in areas similar to VYNE, including dermatology and inflammatory diseases.
Abbvie
ABBV
Mkt Cap369.39B
AbbVie competes in the dermatology space with its portfolio of drugs, directly challenging VYNE's therapeutic areas.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson, through its pharmaceutical division Janssen, offers products that compete in the dermatological and autoimmune sectors against VYNE.
Pfizer
PFE
Mkt Cap161.09B
Pfizer has a broad range of products that include treatments for conditions VYNE targets, making them a direct competitor.
Merck
MRK
Mkt Cap298.84B
Merck operates in similar therapeutic areas as VYNE, including anti-inflammatory and dermatological conditions.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences focuses on inflammatory and respiratory diseases, competing with VYNE's product offerings.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals specializes in biopharmaceuticals for dermatology, directly competing with VYNE.
Novartis
NVS
Mkt Cap297.32B
Novartis offers products in dermatology and chronic diseases, areas where VYNE is also active.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol Myers Squibb has a diverse portfolio that includes treatments for immune-mediated diseases, competing with VYNE.
Astrazeneca
AZN
Mkt Cap315.47B
AstraZeneca has a focus on respiratory, cardiovascular, and autoimmune diseases, overlapping with VYNE's focus areas.

About

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Show more...
CEO
Mr. David T. Domzalski
Employees
13
Country
United States
ISIN
US92941V3087

Listings

XNAS
US
VYNE
BOATS
BOATS
VYNE.BOATS

0 Comments

Share your thoughts

FAQ

What is VYNE Therapeutics stock price today?▼
The current price of VYNE is $0.61 USD — it has decreased by -0.41% in the past 24 hours. Watch VYNE Therapeutics stock price performance more closely on the chart.
What is VYNE Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange VYNE Therapeutics stocks are traded under the ticker VYNE.
Is VYNE Therapeutics stock price growing?▼
VYNE stock has risen by +1.5% compared to the previous week, the month change is a +3.85% rise, over the last year VYNE Therapeutics has showed a -60.77% decrease.
What is VYNE Therapeutics market cap?▼
Today VYNE Therapeutics has the market capitalization of 20.33M
When is the next VYNE Therapeutics earnings date?▼
VYNE Therapeutics is going to release the next earnings report on May 07, 2026.
What is VYNE Therapeutics revenue for the last year?▼
VYNE Therapeutics revenue for the last year amounts to 1.14M USD.
What is VYNE Therapeutics net income for the last year?▼
VYNE net income for the last year is -52.97M USD.
How many employees does VYNE Therapeutics have?▼
As of April 12, 2026, the company has 13 employees.
In which sector is VYNE Therapeutics located?▼
VYNE Therapeutics operates in the Health & Wellness sector.
When did VYNE Therapeutics complete a stock split?▼
The last stock split for VYNE Therapeutics was on February 13, 2023 with a ratio of 1:18.
Where is VYNE Therapeutics headquartered?▼
VYNE Therapeutics is headquartered in Stewartsville, United States.